Austrianova picks A*STAR microfluidics platform for cell dispensing

- Last updated on GMT

Austrianova picks microfluidics platform for cell dispensing
Cell transportation technology firm Austrianova has licensed a low-cost, disposable microfluidics platform from SIMTech to improve how it dispenses cells used in biomanufacturing and therapeutic applications.

Singapore-based Austrianova specialises in enclosing cells and bacteria in protective technologies for the medical, food and biotechnology sectors.

The firm's approach is to mixes cells with a proprietary biocompatible polymer that is then formed into beads and reacted with a second encapsulating polymer.

The  outer-shell of is semi-permeable and allows the influx of nutrients, but does not allow the cells to escape thereby keeping them alive and protected. In a biomedical setting, when the capsules are implanted, the same is also true but in addition the immune cells of the patient cannot enter the capsules.  

Mircofluidics

Zhiping Wang, director SIMTech Microfluidics Foundry told us the licensed "technology consists of polymer devices that were produced by injection molding with microfluidics channels to guide the flow of minute amount of liquid which was disturbed at the exit to generate droplets of precise size and characteristics​."

In a statement SIMTech said that Austrianova will use the tech to control the formation of droplets, explaining that: “The disposable microbead generation device yields high throughput and contamination-free micro-encapsule formation of cells, enzymes or drugs.

The microfluidic dispensing head, which is the droplet generator, is made of disposable polymer chip. As it is disposable, sterilisation is not required. Hence, the downtime of the encapsulated cell manufacturing line is reduced​.”

The license – financial terms of which were not disclosed – was granted by Exploit Technologies Pte, which is the tech transfer arm of SIMTech’s parent organisation, Singapore’s Agency for Science, Technology and Research (A*STAR).

Related news

Show more

Related products

show more

How Viral Safety Testing Will Evolve

How Viral Safety Testing Will Evolve

Viral Safety for mAb: Prevent, Detect, Remove | 20-May-2020 | Event Programme

The pressure to shorten delivery times and reduce costs for biologics are driving an evolution in the biomanufacturing space. Many of the methods used...

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 20-Jan-2020 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Related suppliers

Follow us

Products

View more

Webinars